Shares of Moderna Inc. undefined were down 0.6% in premarket trading on Wednesday after the company said it began dosing patients in a Phase 1/2 clinical...
Shares of Moderna Inc.
were down 0.6% in premarket trading on Wednesday after the company said it began dosing patients in a Phase 1/2 clinical trial evaluating an experimental seasonal flu vaccine. The study is expected to enroll 180 adults and test a vaccine candidate against Type A and Type B influenzas. Moderna has one authorized product, its COVID-19 vaccine, and is using similar mRNA technology to test out other vaccines. Moderna's stock has soared 123.3% so far this year, while the S&P 500 SPX, +0.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más: